SCHEMBL1035534

SCHEMBL1035534

Cc1c(C(=O)NCc2nccs2)sc2nc(-c3ccc(F)cc3)cn12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.73
SMN1; SMN2 Q16637 3/20 0.72
KDM4E B2RXH2 3/20 0.67
LMNA P02545 3/20 0.67
TDP1 Q9NUW8 1/20 0.67
RAB9A P51151 4/20 0.66
HSD17B10 Q99714 3/20 0.66
NPC1 O15118 2/20 0.66
TP53 P04637 3/20 0.65
HPGD P15428 3/20 0.61
NPSR1 Q6W5P4 2/20 0.61
RXFP1 Q9HBX9 1/20 0.61
HTT P42858 1/20 0.60
ALDH1A1 P00352 2/20 0.60
TSHR P16473 4/20 0.60
MEN1 O00255 1/20 0.59
USP2 O75604 1/20 0.59
CASP1 P29466 1/20 0.59
PPARG P37231 1/20 0.59
KMT2A Q03164 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033663 0.85 MAPT (0.70) MAPTSMN1; SMN2KDM4ELMNATDP1
SCHEMBL1032932 0.84 MAPT (0.52) MAPTSMN1; SMN2KDM4ELMNATDP1
SCHEMBL1034699 0.76 RAB9A (0.78) MAPTSMN1; SMN2KDM4ELMNATDP1
SCHEMBL1033294 0.75 TP53 (0.69) MAPTSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL1031278 0.75 LMNA (0.66) MAPTSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL1034707 0.74 LMNA (0.85) MAPTSMN1; SMN2KDM4ELMNARAB9A
SCHEMBL1032028 0.74 MAPT (0.67) MAPTSMN1; SMN2KDM4ELMNATDP1
SCHEMBL1034482 0.74 MAPT (0.76) MAPTSMN1; SMN2KDM4ELMNATDP1
SCHEMBL1032433 0.73 MAPT (0.51) MAPTSMN1; SMN2KDM4ELMNATDP1
SCHEMBL1035549 0.72 TP53 (0.76) MAPTSMN1; SMN2KDM4ELMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086537-B1 IMIDAZO[2,1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-01-26 EP claimed
US-8080569-B2 Imidazo[2,1-b]thiazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-12-20 US disclosed
US-8080569-B2 Imidazo[2,1-b]thiazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-12-20 US disclosed
EP-2086537-B1 IMIDAZO[2,1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-01-26 EP disclosed
EP-2086537-B1 IMIDAZO[2,1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2011-01-26 EP disclosed
US-20100004299-A1 Imidazo[2,1-b]thiazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-01-07 US disclosed
US-20100004299-A1 Imidazo[2,1-b]thiazoles and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-01-07 US disclosed
WO-2008058641-A1 IMIDAZO[2, 1-B]THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004299-A1 Imidazo[2,1-b]thiazoles and their use as pharmaceuticals NOS1, NOS2, NOS3 MAPT 4688/4885SMN1; SMN2 4180/4885KDM4E 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.